| Name | Title | Contact Details |
|---|
At Fox Chase Cancer Center, defeating cancer is our calling. Fox Chase is one of the nation`s first dedicated cancer hospitals, and our researchers and physicians have made major contributions to scientific advancement since our establishment more than a century ago in 1904. Fox Chase scientists have made breakthroughs in cancer prevention, diagnosis, treatment, and survivorship, and have earned the highest awards in their fields, including two Nobel Prizes. We translate these pioneering discoveries into world-class clinical care every day - with a single purpose: to defeat cancer and help the people it impacts. This calling is rooted in our cancer-specific, multidisciplinary teams of doctors, researchers, practitioners, and five-time Magnet designated nurses, who are all more than specialists in cancer; they are international experts in distinct types of cancer, whose deep and focused expertise provides the best chance for the best outcome anywhere along the cancer continuum. And they`re helping to advance the way cancer treatment is delivered around the world. The way we work together, with this single, shared passion for our patients` well-being, is what makes us truly unique.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
Your doctor’s office is now online. From primary care to mental health, we’ve got you covered.
T Z Medical Inc is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Institute for Medical Research is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.